Ozempic and Trulicity are both GLP-1 receptor agonists used in type 2 diabetes, but their ingredients, approved product families and individual prescribing considerations differ. Ozempic contains semaglutide and has both injectable and tablet products; Trulicity contains dulaglutide and is a once-weekly injectable product. A product comparison should begin with the exact formulation and labeled purpose, not the assumption that two GLP-1 brands can be exchanged.
Direct evidence exists for specific injection doses: the 40-week SUSTAIN 7 study compared once-weekly injectable semaglutide with dulaglutide in adults whose type 2 diabetes was inadequately controlled on metformin. It does not establish that every newly marketed dose, oral semaglutide product, or patient will have the same results. Consult the Ozempic product overview for the semaglutide forms before interpreting those findings.
For someone comparing purchase options, the practical next step is to establish which named product a clinician has prescribed, confirm the pharmacy can supply that presentation, and check the applicable formulary. This article explains the clinical and buying distinctions; the separate Trulicity buying guide covers fulfillment and pharmacy checks.
Both medicines activate the GLP-1 receptor, but semaglutide and dulaglutide are different molecules with their own clinical programs and labels. Trulicity is a once-weekly injectable pen; the Ozempic brand includes injection and oral presentations. Comparing the two as if they were identical pens would conceal those formulation differences.
The approved labels also contain product-specific cardiovascular-risk language and age restrictions. Trulicity has labeled glycemic-control use in adults and children aged 10 or older, while the relevant Ozempic presentation and its labeled population must be read separately. A person should not infer pediatric suitability or a new cardiovascular claim from another GLP-1 drug.
SUSTAIN 7 randomized approximately 1,200 adults with type 2 diabetes who were using metformin. It compared semaglutide injection 0.5 mg with dulaglutide 0.75 mg, and semaglutide 1.0 mg with dulaglutide 1.5 mg, for 40 weeks. Its primary endpoint was change in HbA1c; change in body weight was a confirmatory secondary endpoint.
In that study, average HbA1c reductions were 1.5 versus 1.1 percentage points in the lower-dose comparison and 1.8 versus 1.4 percentage points in the higher-dose comparison, respectively. The semaglutide arms also showed greater average weight reduction. Those are group means within one trial—not individualized forecasts, not dose-conversion rules and not proof about oral Ozempic or every higher dulaglutide strength.
Use this table to distinguish actual weekly injectable drugs from a loosely defined GLP-1 category. The direct SUSTAIN 7 evidence came from 40 weeks of treatment in adults with type 2 diabetes taking metformin: semaglutide 0.5 mg and 1 mg were compared with dulaglutide 0.75 mg and 1.5 mg, respectively. The results should inform questions about those arms, not be transposed to oral Ozempic, later dulaglutide strengths or a personalized switching schedule.
A comparison of prescriptions also needs the product-specific indication and pen format. Trulicity has its own age and cardiovascular-risk labeling, and Ozempic injection differs from the tablet presentation. When obtaining a quote, identify the precise prescribed pen, eligible patient population, dispense quantity and actual formulary entry on each side.
| Comparison point | Ozempic (semaglutide) | Trulicity (dulaglutide) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Presentations | Prescription injection; separate oral Ozempic tablets | Prescription once-weekly injectable pens |
| Labeled context | Type 2 diabetes; specific additional injection/tablet indications | Type 2 diabetes; product-specific cardiovascular labeling |
| Direct comparison | SUSTAIN 7: specified semaglutide injection arms | SUSTAIN 7: specified dulaglutide injection arms |
| Buying check | Exact formulation and applicable prescription | Pen strength and applicable prescription |
The trial enrolled a defined population and used particular background therapy, starting HbA1c ranges and study injections. It cannot determine whether an individual should switch medication, whether either product will be covered, or what all current higher-dose comparisons would show. Cross-trial claims that combine SUSTAIN 7 with unrelated studies can magnify differences in populations and follow-up.
Neither a larger mean HbA1c change nor a weight change is a substitute for product-specific safety, kidney or cardiovascular considerations. If the question is which medicine belongs in a wider set of diabetes choices, the Ozempic alternatives guide distinguishes related GLP-1 drugs from different treatment classes.
The compared injections are administered once weekly, but pen operation, strength labeling, training materials, refill quantities and handling instructions are specific to each product. Different devices should not be treated as interchangeable. A pharmacist can confirm how a prescription is written and supplied without substituting a clinically different product on request.
The Ozempic tablet product should not be folded into a weekly-injection comparison: oral semaglutide has its own administration instructions and approval details. For a buyer, route and device preferences may matter, but the clinician first evaluates indicated use, risks and tolerability.
Both agents have boxed warnings involving the risk of thyroid C-cell tumors in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Gastrointestinal adverse reactions and other serious warnings require review of the specific prescription information, especially when the patient uses insulin or another glucose-lowering medicine.
A comparison article cannot rule out pancreatitis, gallbladder disease, dehydration or patient-specific contraindications. Report concerning symptoms promptly to a qualified clinician, and never modify a drug regimen based on a ranking table.
Before shopping, confirm the intended drug name, route, strength, quantity and authorized refills. A licensed U.S. pharmacy needs a valid prescription, and the identity of an online seller should be verified through regulatory records rather than a website badge or discount claim.
The online-pharmacy guidance explains the legitimate channel while Ozempic purchasing steps focus on its branded presentations. No website can guarantee clinical approval or current retail stock.
Even when two drugs treat type 2 diabetes, insurers may place them on different formulary tiers, require different clinical documentation, or process prior authorizations separately. Formularies and pharmacy networks also vary by plan year and contract; price advertisements alone are not a reliable proxy for the final patient amount.
A useful comparison asks the insurer for the exact drug, form and billing quantity, and separately checks self-pay or manufacturer terms. The semaglutide insurance guide explains the broad payer framework, while this page concentrates on the two drugs.
Ask whether the clinician is considering glucose control, another specifically labeled benefit, route of administration, or a history of adverse reactions. Then verify the label for the particular presentation and discuss how evidence from people similar to the patient relates to the actual decision.
Only after that should a purchaser compare fulfillment channels, refill timing and expected out-of-pocket costs. The best pharmacy offer is not necessarily the best clinical option, and the most favorable trial mean does not determine an individual prescription.
SUSTAIN 7 is a valuable direct comparison, but a clinical trial published in 2018 is not a catalog of all U.S. products and label changes in 2026. Contemporary Ozempic and Trulicity labeling may describe additional indications or populations that were not designed as trial endpoints.
For regulatory status rather than efficacy, use the FDA-approved semaglutide directory and check the most current Trulicity label for dulaglutide. Regulatory approval does not establish head-to-head superiority for a new indication.
Instead of asking the pharmacy which GLP-1 is best, ask whether the drug prescribed is the injection or tablet product, whether the written strength and quantity match, whether refills remain, and whether prior authorization is completed. These are questions a pharmacy can answer without taking over medical prescribing.
The total-cost guide can help identify extra visit or delivery fees. A low medication quote does not compensate for a mismatch between the label and prescription.
SUSTAIN 7 provides direct comparative evidence for specific injection strengths, but its results cannot establish the safest medicine for an individual or the outcomes of every newer product presentation. The figures summarized here relate to the trial’s endpoints, population and 40-week follow-up; prescribing information and payment criteria were reviewed separately as of October 19, 2026.
This site is not affiliated with a dispensing pharmacy and cannot certify inventory, insurance coverage or product substitution. Compensation from any linked commercial referral must be disclosed at the link and does not change the editorial distinction between trial evidence, current labeling and a valid pharmacy order.
No. Trulicity contains dulaglutide; Ozempic contains semaglutide. Both are GLP-1 receptor agonists but have distinct labels and prescription products.
No. It reported group-average differences at specific injection doses over 40 weeks in adults with defined type 2 diabetes characteristics. It cannot predict an individual response.
No. The trial compared injectable semaglutide with injectable dulaglutide, not newer oral Ozempic presentations.
Trulicity is a once-weekly injection. Ozempic has a weekly injection presentation and a separate oral tablet presentation with different use instructions.
They are distinct prescription medicines, not interchangeable generics. A prescribing clinician must decide whether a medication change is appropriate.
Their current U.S. labels include warnings about thyroid C-cell tumors and contraindications involving personal or family history of medullary thyroid carcinoma or MEN2.
Its labeled primary use is type 2 diabetes, not a general FDA-approved obesity indication. Outcomes involving weight in diabetes trials do not establish an obesity approval.
Coverage depends on plan, product, indication, pharmacy network and any prior-authorization requirements; it is not guaranteed.
Use U.S. state-board pharmacy records and FDA online-pharmacy safety guidance, and confirm the dispensing pharmacy requires a legitimate prescription.